Efficacy of fipronil/(S)-methoprene/eprinomectin/praziquantel (Broadline®) against *Thelazia callipaeda* in naturally infected cats

Stefania Zanet¹, Simone Morelli², Angela Di Cesare²*, Stefano Bò³, Donato Traversa², Wilfried Lebon⁴, Frederic Beugnet⁴, Giulia Simonato⁵ and Ezio Ferroglio¹

**Abstract**

**Background:** The present clinical field trial was conducted to assess the efficacy of a broad-spectrum parasiticide spot-on formulation containing eprinomectin (Broadline®) against *Thelazia callipaeda* eyeworm in naturally infected cats.

**Methods:** Fifteen privately owned cats harboring at least one live adult *T. callipaeda* were included in the study. Cats were randomly allocated to an untreated control group of seven cats or to a Broadline®-treated group of eight cats. Cats were treated on Day 0; ocular examinations were performed at inclusion and on Days 7 and 14; eyeworms were recovered and counted on Day 14. The primary efficacy assessment was based on group comparison of number of *T. callipaeda* on Day 14.

**Results:** Seven days after treatment, six of eight treated cats were negative for eyeworm infection per visual examination, and on Day 14 no eyeworms were found in the treated cats while the seven untreated cats were still infected (geometric mean: 1.97). All cats had inflammatory ocular signs at inclusion; on Day 14, five of eight treated cats had recovered while all untreated control cats were still symptomatic. All collected parasites were confirmed to be *T. callipaeda* by morphology and molecular characterization.

**Conclusions:** A single treatment with Broadline® provided 100% efficacy against feline thelaziosis and improved related ocular inflammation signs.

**Keywords:** *Thelazia callipaeda*, Cat, Eprinomectin, Broadline®

**Background**

*Thelazia callipaeda* (Spirurida, Thelaziidae) causes an ocular infection in cats, dogs and other mammals, including humans [1–4]. In definitive hosts, adult parasites (“eyeworms”) reside in the conjunctival sac and underneath the third eyelid [5]. After mating, first-stage larvae (L1) are released in conjunctival secretions by female worms. In Europe, L1 are ingested by the zoo-philic males of the fruit fly *Phortica variegata* (Drosophilidae, Steganinae) when feeding on conjunctival fluids. In the intermediate host, L1 develops into infective third-stage larvae (L3) [6]. The transmission to the vertebrate host occurs when the male flies feed again on lachrymal secretions of animals and/or humans [7, 8]. The infection can be subclinical or clinical, and the signs may range from moderate to severe ocular disorders such as
epiphora, blepharitis, conjunctivitis, keratitis and corneal ulceration [9]. In recent years, the enzootic areas of T. callipaeda infection have expanded from Italy to France, Switzerland, Germany, Spain, Portugal, Bosnia and Herzegovina, Croatia, Romania, Bulgaria, Hungary, Greece, Slovakia and Serbia [4, 8, 10]. Recent increases of clinical cases in pets in Europe have stimulated new studies on the control of the infection. Appropriate treatment and prophylaxis are indeed essential to limit the spread of T. callipaeda across Europe and to reduce the risk of zoonotic transmission [4, 11]. Although previous studies have demonstrated the efficacy and safety of topical [12] and oral [13] formulations, therapeutic options for the treatment of feline thelaziosis are limited. The efficacy of the macrocyclic lactone eprinomectin against bovine thelaziosis caused by Thelazia rhodesi has been recently demonstrated [14]. The present study aimed at assessing for the first time the efficacy of Broadline®, a broad-spectrum parasiticide which comprises eprinomectin, combined with fipronil, (S)-methoprene and praziquantel, for the treatment of natural acquired cat thelaziosis.

**Methods**

The present trial was a negative controlled, clinical efficacy study with blinding. Group inclusion was carried out using a randomized block design based on order of inclusion. The study protocol was approved by the Italian Ministry of Health with authorization no. 0024844-08/10/2018-DGSAF-MDS-P. The study was performed in two sites in northern Italy (Piedmont region), in an area known to be enzootic for T. callipaeda infection in pets [10].

**Inclusion and treatment**

Fifteen client-owned cats were included in the study. Cats were of both sexes, aged from 1 to 10 years and weighing 1.7–6.3 kg (Table 1). All cats lived outdoors or were allowed to free-roam.

On Day 0, cats were clinically examined and weighed. Bilateral ocular examination was carried out to assess the presence of eyeworms and of clinical signs potentially related to thelaziosis (e.g. eye scratching, epiphora, purulent exudation, conjunctivitis, keratitis, blepharo-pasm and corneal ulceration). When necessary, one drop of local anesthetic (oxybuprocaine hydrochloride 0.4%) was used on the conjunctiva as a common procedure in ophthalmologic examinations. The infection level was estimated (1 worm, 2–5 worms, >5 worms) by visual inspection of the conjunctival sac in both eyes (Table 2).

After inclusion, cats were allocated into the untreated control, Group 1 (G1), or into Group 2 (G2), treated once with Broadline® according to label instructions. Seven cats were enrolled in G1 and eight cats in G2.

**Post-treatment evaluations and efficacy criteria**

On Days 7 and 14 (±1), cats were assessed for the presence of T. callipaeda by ocular examination and for clinical signs associated with thelaziosis.

On Day 14, the conjunctival fornix was flushed with ~5 ml of saline solution (0.9%) for parasite recovery. Eyeworms were removed, counted separately for each eye and stored in 70% ethanol. All nematodes were identified based on key morphological features [15, 16]. Identification was also confirmed by a PCR specific for a 689-bp-long portion of the gene encoding for the mitochondrial cytochrome c oxidase subunit 1 (cox1) using the primer set NC1–NC2 [17]. PCRs were carried out as previously described [18]. Amplicons were purified and sequenced, and then sequences were determined in both directions and the electropherograms verified by eye with Chromas Lite software. The sequences were aligned using the Data Analysis in Molecular Biology program and Evolution version 4.5.55 (DAMBE) and compared with those available in the GenBank™ using the Basic Local Alignment Search Tool (BLAST).

The primary efficacy criterion for the assessment of curative efficacy was the number of T. callipaeda worms in G2 compared to G1 on Day 14. Counts were transformed to the natural logarithm (ln) of (count +1) for calculation of geometric means for each treatment group (geometric mean = exp (average of ln (worm count +1) within treatment group) – 1). Percent efficacy was calculated using the following formula: 100 × [(C − T)/C], where C is the geometric mean among G1 and T is the geometric mean among G2. The un-transformed counts

**Table 1** Animal and treatment details at inclusion

| Group | Case ID   | Sex | Body weight (kg) | Applicator size (ml) |
|-------|-----------|-----|------------------|----------------------|
| 1     | ITA-01-01 | Male| 3.1              | –                    |
|       | ITA-01-03 | Female| 2.9             | –                    |
|       | ITA-01-06 | Male| 6.3              | –                    |
|       | ITA-01-08 | Male| 3.0              | –                    |
|       | ITA-01-09 | Female| 3.2             | –                    |
|       | ITA-02-01 | Female| 4.0             | –                    |
|       | ITA-02-03 | Male| 5.1              | –                    |
|       | ITA-01-02 | Female| 4.0             | 0.9                  |
|       | ITA-01-04 | Male| 1.7              | 0.9                  |
|       | ITA-01-05 | Female| 3.2             | 0.9                  |
|       | ITA-01-07 | Female| 5.5             | 0.9                  |
|       | ITA-01-10 | Male| 3.7              | 0.9                  |
|       | ITA-02-02 | Male| 4.5              | 0.9                  |
|       | ITA-02-04 | Male| 4.2              | 0.9                  |
|       | ITA-02-05 | Female| 4.0             | 0.9                  |

* Group 1: cats left untreated; Group 2: cats treated with Broadline®
in G2 were compared to the counts in G1 using a non-parametric Wilcoxon rank sum test.

In addition, the proportion of cats positive for *T. callipaeda* worms in the Broadline®-treated group compared to the control group was analyzed. A cat was considered positive if at least one worm was counted in at least one eye on Day 14. The comparison was performed using Fisher’s exact test. The worm-free efficacy (%) was calculated at each time point using the formula: efficacy (%) = ((proportion of positive animals in the control group – proportion of positive animals in the IVP-treated group)/proportion of positive animals in the control group) × 100. Proportions were used as the number of cats was different in both groups.

All testing was two-sided at significance level α = 0.05.

All cats completed the study according to the protocol and were included in the efficacy calculations. After the end of the study, the control cats harboring eyeworms received an appropriate curative treatment.

### Results

At the end of the study (i.e. on Days 14 ± 1), all cats in the control group were still infected with *T. callipaeda* (geometric mean = 1.97) while all cats in G2 were free of infection. There were significantly fewer worms in G2 compared to G1 (p < 0.05) (Tables 2, 3) resulting in a 100% efficacy rate.

On Day 7, six of eight cats in the treated group were negative for eyeworm infection while all cats were negative on Day 14 (Table 2). Efficacy based on the proportion of infected cats was 75% and 100% on Days 7 and 14, respectively, with significantly fewer infected cats in G2 compared to G1 (p-value < 0.05) (Table 4).

The identity of the worms was confirmed morphologically and molecularly. All samples produced PCR products of the expected size. Generated sequences showed 100% homology with *T. callipaeda* GenBank accession number AM042549.1 (haplotype 1).

### Table 2 Individual level of *Thelazia callipaeda* infection on Day 0 and Day 7 and count after flushing on Day 14

| Group坚守 | Case ID | Day 0 Left | Right | Day 7 Left | Right | Day 14 Left | Right | Total |
|-----------|---------|------------|-------|------------|-------|-------------|-------|-------|
| 1         | ITA-01-01 | 2–5        | 1     | 2–5        | 1     | 2           | 1     | 3     |
|           | ITA-01-03 | 2–5        | 2–5   | 2–5        | 2–5   | 2           | 4     | 6     |
|           | ITA-01-06 | 1          | 1     | 1          | 1     | 1           | 1     | 2     |
|           | ITA-01-08 | 0          | 1     | 0          | 1     | 0           | 1     | 1     |
|           | ITA-01-09 | 1          | 0     | 1          | 0     | 1           | 0     | 1     |
|           | ITA-02-01 | 2–5        | 1     | 2–5        | 2–5   | 1           | 1     | 2     |
|           | ITA-02-03 | 1          | 2–5   | 1          | 1     | 0           | 1     | 1     |
| 2         | ITA-01-02 | 0          | 2–5   | 0          | 0     | 0           | 0     | 0     |
|           | ITA-01-04 | 1          | 2–5   | 0          | 0     | 0           | 0     | 0     |
|           | ITA-01-05 | 2–5        | 2–5   | 0          | 0     | 0           | 0     | 0     |
|           | ITA-01-07 | 1          | 0     | 1          | 0     | 0           | 0     | 0     |
|           | ITA-01-10 | 2–5        | 1     | 0          | 0     | 0           | 0     | 0     |
|           | ITA-02-02 | 1          | 1     | 0          | 0     | 0           | 0     | 0     |
|           | ITA-02-04 | 2–5        | 2–5   | 0          | 0     | 0           | 0     | 0     |
|           | ITA-02-05 | 2–5        | 1     | 1          | 0     | 0           | 0     | 0     |

* Group 1: cats left untreated; Group 2: cats treated with Broadline®

### Table 3 Efficacy based on worm count (geometric mean) on Day 14

| Group坚守 | Worm count |
|-----------|------------|
| 1 (n = 7) | 1.97       |
| 2 (n = 8) | 0.0        |
| p-value1  | 0.00052    |
| Efficacy (%) | 100      |

* Group 1: cats left untreated; Group 2: cats treated with Broadline®

1. p-value: Wilcoxon rank sum test

### Table 4 Efficacy based on the number of infected cats on Days 7 and 14

| Group坚守 | Day 7 | Day 14 (±1) |
|-----------|-------|-------------|
| 1 (n = 7) | 7     | 7           |
| 2 (n = 8) | 2     | 0           |
| p-value1  | 0.000013 | 0.000105   |
| Efficacy (%) | 75       | 100         |

* Group 1: cats left untreated; Group 2: cats treated with Broadline®

1. p-value: Fisher’s exact test
At enrollment, all cats showed ocular clinical signs compatible with thelaziosis. At study end, all cats in G1 still showed clinical signs (Table 5). In G2, five cats recovered clinically after the treatment while three remained symptomatic (Table 5). Specifically, one cat that showed epiphora/lacrimation, purulent exudation, conjunctivitis, keratitis and blepharospasm at inclusion presented eye scratching, epiphora/lacrimation, purulent exudation, conjunctivitis and keratitis on Day 7 and eye scratching, epiphora/lacrimation and conjunctivitis on Day 14. The second cat showed eye scratching, epiphora/lacrimation, conjunctivitis and blepharospasm at inclusion and epiphora/lacrimation and conjunctivitis on Days 7 and 14. The third cat showed epiphora/lacrimation, purulent exudation, conjunctivitis and blepharospasm at day 0, eye scratching and conjunctivitis at day 7 and only conjunctivitis at day 14.

Four cats (2 in G1 and 2 in G2) received concomitant treatments during the study (i.e. antibiotics and/or anti-inflammatory drugs) to manage conjunctivitis related to eyeworm infection.

No adverse events occurred during the study.

Discussion

The present study is the first clinical trial evaluating the efficacy of the topical combination containing fipronil/(S)-methoprene/eprinomectin and praziquantel against *T. callipaeda* in naturally infected cats. A single administration of the product was fully efficacious and safe for the elimination of eyeworms within 14 days.

Feline thelaziosis poses important challenges in feline medicine practice because cats may be infected subclinically or show only mild clinical signs overlapping those of other common feline ocular diseases such as ocular viral and/or bacterial infections, which can also secondarily occur in infected cats because of discomfort-caused itching and scratching [9, 19]. Moreover, clinical signs and the presence of eyeworms can be overlooked by veterinarians because in-depth ophthalmic examination in cats commonly requires sedation or general anesthesia as performed for some of the study cats. When thelaziosis is diagnosed, a specific treatment is needed. Therapeutic options for feline ocular thelaziosis in Europe are limited to mechanical removal of the parasites from the eyes or to the administration of some antiparasitic drugs containing macrocyclic lactones. The therapeutic efficacy of an oral dewormer containing milbemycin oxime and a topical containing moxidectin has been demonstrated [12, 13]. Oral milbemycin oxime proved 53.3% and 73.3% effectiveness after one or two treatments at weekly intervals, respectively [13]. The efficacy of the single administration of the spot-on formulation containing moxidectin and imidacloprid was 93.3% and 100% 14 and 28 days post-treatment, respectively [12]. The latter is approved in the EU for treating *T. callipaeda* infection in cats.

Now, the administration of Broadline® has also demonstrated 100% efficacy in the treatment of cats who were cleared of *T. callipaeda* within 2 weeks. The post-treatment clinical recovery of five cats in 14 days and the significant reduction of the clinical signs in three treated animals further support the usefulness of this formulation in feline clinical practice. According to the data generated herein, the concomitant administration of anti-inflammatory drugs could be of benefit to obtain a faster clinical recovery in severely infected cats and to guarantee animal welfare.

In general, feline vector-borne diseases are often underestimated, and there is a need to increase awareness on their importance for cats [20–22]. According, correct diagnosis and effective treatments of cats infected with vector-borne pathogens, such as *T. callipaeda*, should be implemented to limit their spreading and the risk of infections for both animals and humans. Although cases of infection by *T. callipaeda* in humans

---

### Table 5

| Clinical Sign | G1 (Day 0) | G2 (Day 0) | G1 (Day 7) | G2 (Day 7) | G1 (Day 14) | G2 (Day 14) |
|---------------|------------|------------|------------|------------|------------|------------|
| Eye scratching | 3/7 (42.9) | 2/8 (25)   | 3/7 (42.9) | 3/8 (37.5) | 2/7 (28.6) | 1/8 (12.5) |
| Epiphora/lacrimation | 6/7 (85.7) | 8/8 (100)  | 6/7 (85.7) | 5/8 (62.5) | 6/7 (85.7) | 3/8 (37.5) |
| Purulent exudation | 3/7 (42.9) | 4/8 (50)   | 3/7 (42.9) | 1/8 (12.5) | 3/7 (42.9) | 0/8 (0)    |
| Conjunctivitis | 5/7 (71.4) | 8/8 (100)  | 6/7 (85.7) | 7/8 (87.5) | 6/7 (85.7) | 3/8 (37.5) |
| Keratitis | 0 (0)      | 0 (0)      | 0 (0)      | 0 (0)      | 0 (0)      | 0 (0)      |
| Blepharospasm | 2/7 (28.6) | 5/8 (62.5) | 2/7 (28.6) | 1/8 (12.5) | 2/7 (28.6) | 0/8 (0)    |
| Total number of cats with clinical signs | 7/7 (100) | 8/8 (100)  | 7/7 (100) | 8/8 (100)  | 7/7 (100) | 3/8 (37.5) |

Group 1: cats left untreated; Group 2: cats treated with Broadline®
have been reported from different European countries (e.g. Italy, France, Spain, Serbia, Croatia and Germany), human thelaziosis in this continent is still regarded as a rare disease [4]. Considering the zoonotic nature of the infection, preventive measures should also be implemented in enzootic areas to reduce the occurrence of the disease. The monthly administration of antiparasitic drugs containing macrocyclic lactones, i.e. oral milbemycin oxime (0.5 mg/kg b.w.) (NexGard® Spectra) and moxidectin spot-on (2.5%) (Advocate®), is effective in preventing thelaziosis in dogs [23, 24]. Considering that the topical combination containing fipronil, (S)-methoprene, eprinomectin and praziquantel is highly efficacious against developing stages of lungworms and heartworms [25–27], its efficacy in preventing the establishment of adult *Thelazia* in cats is worth of further studies.

**Conclusions**

In the present study, a single treatment with Broadline® provided 100% efficacy against *Thelazia* infection in cats and improved thelaziosis-related ocular inflammation signs.

**Abbreviations**

L1: First-stage larvae; L3: Third-stage larvae; G1: Group 1, cats left untreated; G2: Group 2, cats treated with Broadline®, PCR: Polymerase chain reaction.

**Acknowledgements**

The authors acknowledge the valuable help of the owners of the cats who kindly allowed the completion of the study.

**Authors’ contributions**

SZ drafted the first versions of the article and participated in the field activities. SB and EF participated in the field activities as investigators. SM and GS participated in enzootic areas to reduce the occurrence of the disease. The monthly administration of antiparasitic drugs containing macrocyclic lactones, i.e. oral milbemycin oxime (0.5 mg/kg b.w.) (NexGard® Spectra) and moxidectin spot-on (2.5%) (Advocate®), is effective in preventing thelaziosis in dogs [23, 24]. Considering that the topical combination containing fipronil, (S)-methoprene, eprinomectin and praziquantel is highly efficacious against developing stages of lungworms and heartworms [25–27], its efficacy in preventing the establishment of adult *Thelazia* in cats is worth of further studies.

**Conclusions**

In the present study, a single treatment with Broadline® provided 100% efficacy against *Thelazia* infection in cats and improved thelaziosis-related ocular inflammation signs.

**Abbreviations**

L1: First-stage larvae; L3: Third-stage larvae; G1: Group 1, cats left untreated; G2: Group 2, cats treated with Broadline®, PCR: Polymerase chain reaction.

**Acknowledgements**

The authors acknowledge the valuable help of the owners of the cats who kindly allowed the completion of the study.

**Authors’ contributions**

SZ drafted the first versions of the article and participated in the field activities. SB and EF participated in the field activities as investigators. SM and GS participated in the laboratory activities. DT, FB and WL conceived the study. ADC, DT and WL supervised the study and revised the manuscript. All authors read and approved the final manuscript.

**Funding**

The present study was funded by Boehringer Ingelheim Animal Health France SCS.

**Availability of data and materials**

All relevant data are included within the article.

**Declarations**

**Ethics approval and consent to participate**

Approval to conduct the study was obtained beforehand from the regulatory authority (Italian Health Ministry, authorization no. 0024844-08/10/2018-DGSAF-MDS-P) and animals were included in the study pending written informed consent from the owner.

**Consent for publication**

Not applicable.

**Competing interests**

The authors SZ, SM, ADC, SB, DT, GS, EF declare that they have no conflict of interest. The authors WL and FB are employees of Boehringer Ingelheim Animal Health, Lyon, France, which sponsored the present study.

**Author details**

1. Department of Veterinary Sciences, University of Turin, Turin, Italy. 2. Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy. 3. Ambulatorio Veterinario Bo-Ferro, Turin, Italy. 4. Boehringer Ingelheim Animal Health, Lyon, France. 5. Department of Animal Medicine, Production and Health, University of Padua, Padua, Italy.

**Received: 24 June 2021  Accepted: 28 August 2021**

**Published online: 15 September 2021**

**References**

1. Anderson RC. Nematode parasites of vertebrates. Their development and transmission. Guilford, UK: CAB Publishing. 2000.
2. Soares C, Ramalho Sousa S, Anastácio S, Goretí Matias M, Marquês I, Mascarenhas S, João Vieira M, de Carvalho LM, Otranto D. Feline thelaziosis caused by *Thelazia callipaeda* in Portugal. Vet Parasitol. 2013;196:528–31.
3. Hodžić A, Latrofa MS, Anionicca G, Alíc A, Beck R, Lia RP, Dantas-Torres F. Otranto D. The spread of zoonomic *Thelazia callipaeda* in the Balkan area. Parasit Vectors. 2014;7:352.
4. Do Vale B, Lopes AP, da Conceição Fontes M, Silvestre M, Cardoso L, Coelho AC. Thelaziosis due to *Thelazia callipaeda* in Europe in the 21st century—a review. Vet Parasitol. 2019;275:108957.
5. Otranto D, Traversa D. *Thelazia* eye worm: an original endo- and ecto-parasitic nematode. Trends Parasitol. 2005;21:1–4.
6. Otranto D, Lia RP, Cantacessi C, Testini G, Troccoli A, Shen JL, Wang ZX. Nematode biology and larval development of *Thelazia callipaeda* (Spirurida, Thelazidae) in the drosophilid intermediate host in Europe and China. Parasitology. 2005;131(1 Pt 6):847–55.
7. Otranto D, Cantacessi C, Testini G, Lia RP. *Phorica variiegata* as an intermediate host of *Thelazia callipaeda* under natural conditions: evidence for pathogen transmission by a male arthropod vector. Int J Parasitol. 2006;36:1167–73.
8. Palfreyman J, Graham-Brown J, Caminade C, Gilmore P, Otranto D, Williams DJL. Predicting the distribution of *Phorica variiegata* and potential for *Thelazia callipaeda* transmission in Europe and the United Kingdom. Parasit Vectors. 2018;11:272.
9. Motta B, Nágel F, Nágel C, Solari-Basano F, Schiessl B, Deplazes P, Schynder M. Epidemiology of the eye worm *Thelazia callipaeda* in cats from southern Switzerland. Vet Parasitol. 2014;203:287–93.
10. Otranto D, Ferroglio E, Lia RP, Traversa D, Rossi L. Current status and epidemiological observation of *Thelazia callipaeda* (Spirurida, Thelazidae) in dogs, cats and foxes in Italy: a “coincidence” or a parasitic disease of the Old Continent? Vet Parasitol. 2003;116:315–25.
11. Marino V, Montoya A, Mascarauñ C, Domínguez I, Gálvez R, Hernández M, Zentker C, Checa R, Sarquis J, Carrera JP, Porterio M, Miró G. Feline thelaziosis (*Thelazia callipaeda*) in Spain: state-of-the-art and first prophylactic trial in cats. J Feline Med Surg. 2021;1098612X21997625.
12. Otranto D, Solari Basano F, Pombi M, Capelli G, Nazzari R, Falzone L, Petry G, Pollmeier MG, Lia RP. Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by *Thelazia callipaeda* in naturally infected cats. Parasit Vectors. 2019;12:25.
13. Motta B, Schynder M, Basano FS, Nágel F, Nágel C, Schiessl B, Mallia E, Lia RP, Dantas-Torres F, Otranto D. Therapeutic efficacy of milbemycin oxime/praziquantel oral formulation (Milbemax®) against *Thelazia callipaeda* in naturally infested dogs and cats. Parasit Vectors. 2012;5:85.
14. Deak G, Ioncă AM, Olos NV, Gherman CM, Mihalca AD. *Thelazia rhodesi* in a dairy farm in Romania and successful treatment using eprinomectin. Parasitol Int. 2021;1098612X21997625.
15. Skrabin KI, Sobolev AA, Ivashkin VM. Essentials of Nematology, Vol XVI: Spirurata of animals and man and the diseases caused by them. Part 4 Thelazioidea. Moscow: Izdatel’sto Akademii Nauk SSSR. 1967.
16. Otranto D, Lia RP, Traversa D, Giannetto S. *Thelazia callipaeda* (Spirurida, Thelaziidae) of carnivores and humans: morphological study by light and scanning electron microscopy. Parasitologia. 2003;45:125–33.

17. Casiraghi M, Anderson TJ, Bandi C, Bazzocchi C, Gerbi C. A phylogenetic analysis of filarial nematodes: comparison with the phylogeny of Wolbachia endosymbionts. Parasitology. 2001;122:93–103.

18. Otranto D, Testini G, De Luca F, Hu M, Samoli S, Gasser RB. Analysis of genetic variability within *Thelazia callipaeda* (Nematoda: Thelazioidea) from Europe and Asia by sequencing and mutation scanning of the mitochondrial cytochrome c oxidase subunit I gene. Mol Cell Probes. 2003;19:306–13.

19. Silva LMR, Spoerel S, Wiesner L, Klein M, Pantchev N, Taubert A, Hermosilla C. Ophthalmic *Thelazia callipaeda* infections: first feline and new canine imported cases in Germany. Parasitol Res. 2020;119:3099–104.

20. Day MJ. Cats are not small dogs: is there an immunological explanation for why cats are less affected by arthropod-borne disease than dogs? Parasit Vectors. 2016;9:507.

21. Morelli S, Crisi PE, Di Cesare A, De Santis F, Barlaam A, Santoprete G, Parrinello C, Palermo S, Mancini P, Traversa D. Exposure of client-owned cats to zoonotic vector-borne pathogens: clinic-pathological alterations and infection risk analysis. Comp Immunol Microbiol Infect Dis. 2019;66:101344.

22. Morelli S, Colombo M, Dimzas D, Barlaam A, Traversa D, Di Cesare A, Russi L, Spoletini R, Paoletti B, Dikou A. Leishmaniasis infantum Seroprevalence in cats from touristic areas of Italy and Greece. Front Vet Sci. 2020;7:616566.

23. Lebon W, Guillot J, Álvarez MJ, Antonio Bazaga J, Cortes-Dubly ML, Dumont P, Eberhardt M, Gómez H, Peninont O, Siméon N, Beugnet F, Halos L. Prevention of canine ocular thelaziosis (*Thelazia callipaeda*) with a combination of milbemycin oxime and afoxolaner (Nexgard Spectra®) in endemic areas in France and Spain. Parasite. 2014;20:61.

24. Marino V, Gálvez R, Masculán C, Domínguez I, Sarquis J, Montoya A, Barrera JP, Zenker C, Checa R, Hernández M, Miró G. Update on the treatment and prevention of ocular thelaziosis (*Thelazia callipaeda*) in naturally infected dogs from Spain. Int J Parasitol. 2021;51:73–81.

25. Baker CF, Tielemans E, Pollmeier MG, McCall JW, McCall SD, Irwin J, Chester ST, Carithers DS, Rosentel JK. Efficacy of a single dose of a novel topical combination product containing eprinomectin to prevent heartworm infection in cats. Vet Parasitol. 2014;202:49–53.

26. Knaus M, Chester ST, Rosentel J, Kühnet A, Rehbein S. Efficacy of a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel against larval and adult stages of the cat lungworm *Aelurostrongylus abstrusus*. Vet Parasitol. 2014;202:64–8.

27. Knaus M, Visser M, Mayr S, Rehbein S. Efficacy of a topical combination of eprinomectin, praziquantel, fipronil and (S)-methoprene against developing and adult *Troglostrongylus brevior* lungworms (Nematoda, Crenosomatidae) in cats. Vet Parasitol. 2020;289:108578.

**Publisher's Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Ready to submit your research?** Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions